check_circleStudy Completed
Multiple Sclerosis
Bayer Identifier:
91713
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
BENEFIT Extension Study
Trial purpose
To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.
Key Participants Requirements
Sex
BothAge
23 - 50 YearsTrial summary
Enrollment Goal
283Trial Dates
September 2007 - January 2011Phase
N/ACould I Receive a placebo
NoProducts
Betaseron (Interferon beta-1b, BAY86-5046)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Canada | |
Completed | Many Locations, Switzerland | |
Completed | Many Locations, Hungary | |
Completed | Many Locations, Israel | |
Completed | Many Locations, Norway | |
Completed | Many Locations, Sweden | |
Completed | Many Locations, Austria | |
Completed | Many Locations, Belgium | |
Completed | Many Locations, Poland | |
Completed | Many Locations, Denmark | |
Completed | Many Locations, Slovenia | |
Completed | Many Locations, Czech Republic | |
Completed | Many Locations, Italy | |
Completed | Many Locations, Finland | |
Completed | Many Locations, Germany | |
Completed | Many Locations, France | |
Terminated | Many Locations, Netherlands | |
Completed | Many Locations, Spain |
Primary Outcome
- To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Studydate_rangeTime Frame:End of Studyenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A